ストックスクリーナーアプリを入手
23.20
1.61%
-0.35
前日終値:
$23.55
開ける：
$23.37
24時間の取引高:
308.52K
Relative Volume:
0.26
時価総額：
$1.75B
収益：
$122.87M
当期純損益:
$-73.68M
株価収益率:
-23.67
EPS:
-0.9803
ネットキャッシュフロー:
$-39.27M
1週間 パフォーマンス:
-1.28%
1か月 パフォーマンス:
-13.51%
6か月 パフォーマンス:
+62.14%
1年 パフォーマンス:
+56.34%
1日の値動き範囲:
$23.12
$23.76
1週間の範囲:
$22.80
$24.31
52週間の値動き範囲:
$9.03
$28.49
Zymeworks Inc. Stock (ZYME) Company Profile
名前
Zymeworks Inc.
セクター
電話
604-678-1388
住所
1385 West 8th Avenue, Suite 540, Vancouver, BC
ZYME を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
23.20 | 1.78B | 122.87M | -73.68M | -39.27M | -0.9803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.62 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.90 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.06 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-12 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 再開されました | Wells Fargo | Equal Weight |
| 2025-10-14 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 開始されました | B. Riley Securities | Buy |
| 2025-05-20 | 開始されました | TD Cowen | Buy |
| 2024-12-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-07 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 再開されました | Wells Fargo | Overweight |
| 2023-01-04 | 繰り返されました | H.C. Wainwright | Neutral |
| 2022-12-20 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 再開されました | Wells Fargo | Overweight |
| 2022-05-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-03-15 | 開始されました | Evercore ISI | Outperform |
| 2021-12-10 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 再開されました | Guggenheim | Neutral |
| 2021-10-07 | 開始されました | Jefferies | Hold |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-02-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 再開されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-08-06 | 開始されました | SVB Leerink | Outperform |
| 2020-01-10 | 開始されました | Wolfe Research | Outperform |
| 2019-12-09 | 開始されました | JP Morgan | Neutral |
| 2019-11-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-30 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 開始されました | Stifel | Buy |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-05-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 開始されました | Raymond James | Outperform |
すべてを表示
Zymeworks Inc. (ZYME) 最新ニュース
Analyst Upgrade: Does Zymeworks Inc have strong EBITDA marginsPortfolio Risk Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Zymeworks to Showcase Innovative Biotherapeutics at Upcoming Conferences - MSN
A Look At Zymeworks (ZYME) Valuation After Positive HERIZON GEA 01 Trial Results And Royalty Milestone Potential - Sahm
New Highs: Can Hippo Holdings Inc lead its sector in growthQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Aug Analyst Calls: What is the earnings history of Zymeworks IncJuly 2025 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Zymeworks (NYSE:ZYME) Shares Down 5.5%Here's Why - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares By Investing.com - Investing.com Nigeria
Zymeworks (NYSE:ZYME) COO Mark Hollywood Sells 6,120 Shares - MarketBeat
Hollywood mark, EVP at Zymeworks, sells $138k in shares - Investing.com
Zymeworks appoints industry veteran Brian Cherry to board By Investing.com - Investing.com Nigeria
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 9,310 Shares - MarketBeat
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 9,560 Shares - MarketBeat
Zymeworks EVP Smith sells shares for $211,090 By Investing.com - Investing.com Australia
Zymeworks CSO Moore sells $216k in shares By Investing.com - Investing.com Nigeria
Zymeworks EVP Smith sells shares for $211,090 - Investing.com
Zymeworks CSO Moore sells $216k in shares - Investing.com
Insider Selling: Zymeworks (NYSE:ZYME) CEO Sells 30,424 Shares of Stock - MarketBeat
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy - The Globe and Mail
What's Driving Zymeworks Stock Higher? - Nasdaq
Zymeworks Makes Leadership, Board Changes; Begins CFO Search - marketscreener.com
Zymeworks Reshapes Board and Executive Team to Support Next Phase of Growth - TipRanks
Zymeworks appoints industry veteran Brian Cherry to board - Investing.com
Zymeworks Inc. Announces Chief Financial Officer Changes - marketscreener.com
HERIZON-GEA-01 Trial Highlights Zymeworks’ Path To $440M Milestones And Growth (ZYME) - Seeking Alpha
Zymeworks (ZYME) Reports Positive Phase 3 Trial Results for Ziih - GuruFocus
Zymeworks reports positive phase 3 Ziihera data; cash runway extended beyond 2028 - Seeking Alpha
Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth - TipRanks
Zymeworks Reports Positive Phase 3 Results for Ziihera® in HER2-Positive Gastroesophageal Adenocarcinoma, Announcing Strategic Priorities for 2026 - Quiver Quantitative
Zymeworks Outlines Strategic Priorities and Outlook for 2026 - The Manila Times
Zymeworks outlines strategic priorities and outlook for 2026 - marketscreener.com
Aug Macro: Is Zymeworks Inc. stock vulnerable to regulatory risksQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
Can Zymeworks Inc. stock hit analyst price targetsWeekly Volume Report & Weekly Top Performers Watchlists - Улправда
Zymeworks Inc. (ZYME) Stock Analysis: A 53.85% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
Earnings Beat: How Zymeworks Inc stock reacts to oil pricesJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - moha.gov.vn
How Zymeworks Inc. stock reacts to oil pricesShare Buyback & Weekly Stock Performance Updates - Улправда
Zymeworks (ZYME) Is Down 5.6% After Positive Phase 3 Ziihera Data Unlocks US$440 Million Milestones - simplywall.st
Will Zymeworks Inc. stock benefit from upcoming earnings reportsTrend Following Strategies & Affordable Trading Plans - ulpravda.ru
Oklahoma City NewsThe Oklahoman - FinancialContent
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Benzinga
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial - Sahm
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial - TipRanks
Zymeworks Reports Positive Phase 3 HERIZON-GEA-01 Results for Ziihera as Potential New Standard of Care in HER2-Positive First-Line Metastatic GEA - Quiver Quantitative
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire
Redlands Daily Facts - FinancialContent
Zymeworks Inc. (ZYME) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.05%
大文字化:
|
ボリューム (24 時間):